Cargando…
Quantifying the Benefits of Digital Biomarkers and Technology-Based Study Endpoints in Clinical Trials: Project Moneyball
INTRODUCTION: Digital biomarkers have significant potential to transform drug development, but only a few have contributed meaningfully to bring new treatments to market. There are uncertainties in how they will generate quantifiable benefits in clinical trial performance and ultimately to the chanc...
Autores principales: | Mori, Hiromasa, Wiklund, Stig Johan, Zhang, Jason Yuren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297703/ https://www.ncbi.nlm.nih.gov/pubmed/35949224 http://dx.doi.org/10.1159/000525255 |
Ejemplares similares
-
Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective
por: Stephenson, Diane, et al.
Publicado: (2021) -
The Search for Surrogate Endpoints in Trials in Diffuse Large B‐Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project
por: Sargent, Daniel J., et al.
Publicado: (2017) -
Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease
por: Insel, Philip S, et al.
Publicado: (2015) -
Increasing the use of mobile technology–derived endpoints in clinical trials
por: Herrington, William G, et al.
Publicado: (2018) -
Helicopter EMS: Research Endpoints and Potential Benefits
por: Thomas, Stephen H., et al.
Publicado: (2012)